Overview
- P&G CEO Shailesh Jejurikar told CNBC that the company will pay $3.8 billion for Thorne and that a formal announcement would follow later the same day.
- The reported price sits within recent market talk that valued Thorne as high as $4 billion and follows its 2023 sale to L Catterton for $680 million.
- The acquisition would broaden P&G’s supplements lineup, which already includes Metamucil and Align Probiotic, and deepen its push into consumer self-care.
- Reporters seeking details said P&G and Thorne had not provided immediate comment, leaving financing, regulatory clearance and integration plans unclear.
- Analysts cite rising demand for preventive health and interest linked to weight-loss drugs as drivers for consolidation in the supplements market, a trend that could reshape competition and product availability.